Furthermore, the combination of anti-VEGF/VEGFR and PD-1/PD-L1 inhibitors has been granted FDA approval for the treatment of hepatocellular carcinoma and renal cell carcinoma [63–65]. The gene discussed is VEGFA; the disease is renal cell carcinoma.